Business Insider
My Markets Watchlist
Markets Stocks

Summit Therapeutics Inc Registered Shs Stock , SMMT

20.58 +0.87 +4.41%
03:59:59 PM EDT 6/6/2025 BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 06/06/2025 the closing price of the Summit Therapeutics Inc Registered Shs share was $19.71 on BTT. Compared to the opening price on Friday 06/06/2025 on BTT of $20.08, this is a drop of 1.88%. Summit Therapeutics Inc Registered Shs's market capitalization is $11.97 B by 737.68 M shares outstanding.
Is Summit Therapeutics stock a Buy, Sell or Hold? Summit Therapeutics stock has received a consensus rating of buy. The average rating score is and is based on 12 buy ratings, 0 hold ratings, and 0 sell ratings.
What was the 52-week low for Summit Therapeutics stock? The low in the last 52 weeks of Summit Therapeutics stock was 6.79. According to the current price, Summit Therapeutics is 303.32% away from the 52-week low.
What was the 52-week high for Summit Therapeutics stock? The high in the last 52 weeks of Summit Therapeutics stock was 36.91. According to the current price, Summit Therapeutics is 55.76% away from the 52-week high.
What are analysts forecasts for Summit Therapeutics stock? The 12 analysts offering price forecasts for Summit Therapeutics have a median target of 29.83, with a high estimate of 44.00 and a low estimate of 7.00. The median estimate represents a 68.98 difference from the last price of 20.58.

Summit Therapeutics Stock Snapshot

17.87
Bid
100.00
Bid Size
23.36
Ask
100.00
Ask Size
6/6/2025
Date
3:59 PM
Time
127,462.00
Volume
19.71
Prev. Close
20.08
Open
15.19 B
Market Cap in USD
737.68 M
Number of Shares
737.68 M
Total Number of Shares
19.96
Day Low
21.20
Day High
20.58
6.79
52 Week Low
36.91
52 Week High
20.58
0.00
Dividend in USD
0.00
Dividend Yield
14.95
Free Float in %
-0.31
EPS in USD
0.53
Book Value per Share in USD
-0.20
Cash Flow per Share in USD

Historical Prices for Summit Therapeutics

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Summit Therapeutics Analyst Data

Total Analysts: 12
Buy Ratings: 12 Neutral Ratings: 0 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 7.00 Median: 29.83 Highest: 44.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Summit Therapeutics Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
06/02/25 JMP Securities LLC
Maintained Buy $40
05/02/25 Goldman Sachs
Maintained Buy $41
04/28/25 JMP Securities LLC
Maintained Buy $40
04/25/25 Jefferies & Company Inc.
Maintained Buy $44
04/23/25 Cantor Fitzgerald
Maintained Buy
03/26/25 Citigroup Corp.
Upgraded to Buy $35
03/21/25 Cantor Fitzgerald
Maintained Buy
03/12/25 Evercore
Maintained Buy $30
02/28/25 Goldman Sachs
Maintained Buy $42
02/25/25 H.C. Wainwright & Co.
Maintained Buy $44
06/03/24 Stifel, Nicolaus & Co., Inc.
Maintained Buy $14
05/31/24 Citigroup Corp.
Maintained Buy $13
05/07/24 Citigroup Corp.
Maintained Buy $7
03/26/24 Stifel, Nicolaus & Co., Inc.
Maintained Buy $8

Summit Therapeutics Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 0 32 171 1,148 2,876
Dividend 0.00 0.00 0.00 - -
Dividend Yield (in %) 0.00 % 0.00 % 0.00 % - -
EPS -0.41 -0.56 -0.61 0.09 1.41
P/E Ratio -50.67 -36.91 -33.57 224.51 14.56
EBIT -315 -447 -497 177 1,360
EBITDA -310 -443 -582 - -
Net Profit -302 -424 -469 107 1,103
Net Profit Adjusted -299 -577 -829 -1,337 -1,180
Pre-Tax Profit -307 -441 -491 171 1,366
Pre-Tax Profit Reported -322 -503 -557 -197 -133
EPS (Non-GAAP) ex. SOE - - - - -
EPS (GAAP) -0.42 -0.56 -0.53 0.46 1.82
Gross Income 0 16 172 739 1,651
Cash Flow from Investing 251 -1 -1 -1 -2
Cash Flow from Operations -238 -325 -312 436 1,390
Cash Flow from Financing 129 550 275 0 0
Cash Flow per Share - - - - -
Free Cash Flow - - - - -
Free Cash Flow per Share - - - - -
Book Value per Share - - - - -
Net Debt -74 -188 -27 - -
Research & Development Exp. 234 324 392 451 486
Capital Expenditure 1 1 1 2 3
Selling, General & Admin. Exp. 77 128 186 280 391
Shareholder’s Equity 198 380 268 753 2,078
Total Assets 286 446 345 851 2,198
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 11 11 11 11
Average Estimate - -0.093 USD -0.103 USD -0.406 USD -0.558 USD
Year Ago - -0.085 USD -0.077 USD -0.308 USD -
Publish Date - 8/6/2025 11/5/2025 - -
Revenue Estimates
No. of Analysts - 9 9 10 10
Average Estimate - 0 USD 0 USD 0 USD 32 USD
Year Ago - 0 USD 0 USD 0 USD -
Publish Date - 8/6/2025 11/5/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 0.00 0.00 0.71 1.81 0.86 0.81 33.04
Change of sales in % - -100.00 -61.03 110.35 5.99 - 969.94
Gross profit on sales -0.09 -2.05 -1.81 - - - -
Gross profit on sales change in % 95.66 -13.32 - - - - -
Operating income -211.30 -89.74 -79.30 -107.15 -71.65 -54.90 -17.06
Operating income change in % -135.47 -13.16 25.99 -49.56 -30.50 - 47.51
Income before tax -221.63 -615.87 -83.31 -103.81 -62.27 -36.47 -14.19
Income before tax change in % 64.01 -639.30 19.75 -66.70 -70.75 - 58.59
Income after tax -221.32 -614.93 -78.78 -88.60 -52.70 -30.66 -9.27
Income after tax change in % 64.01 -680.54 11.08 -68.13 -71.86 - 67.46

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 46.81 125.26 537.51 30.09 23.05 18.41 62.69
Long-term liabilities per share 0.01 0.15 2.36 0.05 0.04 0.02 0.49
Equity 388.75 77.69 126.65 83.28 79.45 78.46 14.04
Equity change in % 400.37 -38.66 52.07 4.82 1.27 - -
Balance sheet total 435.56 202.95 664.17 113.37 102.50 96.87 76.74
Balance sheet total change in % 114.62 -69.44 485.82 10.61 5.81 - 62.27

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 0.00 0.00 0.00 0.02 0.01 0.00 0.50
P/E ratio (year end quote, basic EPS) - - - - - - -
P/E ratio (year end quote, diluted EPS) - - - - - - -
Dividend yield in % 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Equity ratio in % 89.25 38.28 19.07 73.46 77.52 80.99 18.30
Debt ratio in % 10.75 61.72 80.93 26.54 22.48 19.01 81.70

Summit Therapeutics Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Zanganeh Maky 05/29/2025 74,545.00 555,754,696.00 2.64 Buy No
DUGGAN ROBERT W 05/29/2025 74,545.00 555,754,696.00 2.64 Buy No
Zanganeh Maky 04/07/2025 3,985,055.00 555,680,151.00 1.58 Buy No
DUGGAN ROBERT W 04/07/2025 3,985,055.00 555,680,151.00 1.58 Buy No
Zanganeh Maky 09/10/2024 44,052.00 24,967,852.00 22.70 Buy No
Soni Manmeet Singh 09/10/2024 44,052.00 3,020,242.00 22.70 Buy No
Huber Jeff 09/10/2024 44,052.00 44,052.00 22.70 Buy No
Anand Bhaskar 09/10/2024 22,026.00 131,426.00 22.70 Buy No
DUGGAN ROBERT W 09/10/2024 3,325,991.00 551,695,096.00 22.70 Buy No
Zanganeh Maky 03/26/2024 20,000.00 50,000.00 3.71 Buy No
Zanganeh Maky 03/26/2024 34,321.00 24,923,800.00 3.72 Buy No
Zanganeh Maky 03/26/2024 26,000.00 520,814.00 3.72 Buy No
Zanganeh Maky 03/25/2024 30,000.00 30,000.00 3.75 Buy No
Dhingra Ankur 03/25/2024 100,000.00 354,958.00 3.75 Buy No
Dhingra Ankur 12/12/2023 19,700.00 254,958.00 2.17 Buy No
Dhingra Ankur 12/12/2023 700.00 235,258.00 2.15 Buy No
Zanganeh Maky 12/11/2023 5,000.00 494,814.00 2.07 Buy No
Zanganeh Maky 12/10/2023 315,681.00 24,889,479.00 1.58 Buy No
Zanganeh Maky 12/10/2023 489,814.00 489,814.00 1.44 Buy No
Soni Manmeet Singh 10/12/2023 2,976,190.00 2,976,190.00 1.68 Buy No
Zanganeh Maky 03/07/2023 6,748,629.00 9,884,095.00 1.05 Buy No
Zanganeh Maky 03/07/2023 16,778,415.00 24,573,798.00 1.05 Buy No
Zanganeh Maky 03/07/2023 6,748,629.00 9,884,095.00 1.05 Buy No
Zanganeh Maky 03/07/2023 804,672.00 1,178,529.00 1.05 Buy No
Zanganeh Maky 03/07/2023 15,973,743.00 23,395,269.00 1.05 Buy No

Summit Therapeutics Dividend Calendar

Date Name Dividend *yield Currency
2024 Summit Therapeutics Inc Registered Shs 0.00 0.00 USD
2023 Summit Therapeutics Inc Registered Shs 0.00 0.00 USD
2022 Summit Therapeutics Inc Registered Shs 0.00 0.00 USD
2021 Summit Therapeutics Inc Registered Shs 0.00 0.00 USD
2020 Summit Therapeutics Inc Registered Shs 0.00 0.00 USD
2019 Summit Therapeutics Inc Registered Shs 0.00 0.00 USD
2018 Summit Therapeutics Inc Registered Shs 0.00 0.00 USD
2017 Summit Therapeutics Inc Registered Shs 0.00 0.00 USD
2016 Summit Therapeutics Inc Registered Shs 0.00 0.00 USD
2015 Summit Therapeutics Inc Registered Shs 0.00 - USD
2014 Summit Therapeutics Inc Registered Shs 0.00 - USD
2013 Summit Therapeutics Inc Registered Shs 0.00 - USD
2012 Summit Therapeutics Inc Registered Shs 0.00 - USD
2011 Summit Therapeutics Inc Registered Shs 0.00 - USD
2010 Summit Therapeutics Inc Registered Shs - - USD
2009 Summit Therapeutics Inc Registered Shs - - USD
*Yield of the Respective Date

Summit Therapeutics Calendar

Event Estimate Info Date
Annual General Meeting -0.310 USD Annual General Meeting 06/12/2025
Earnings Report -0.093 USD Q2 2025 Earnings Release 08/06/2025
Earnings Report -0.104 USD Q3 2025 Earnings Release 11/05/2025
Earnings Report -0.127 USD Q4 2025 Earnings Release 03/12/2026
Earnings Report -0.121 USD Q1 2026 Earnings Release 05/07/2026

Summit Therapeutics Past Events

Event Actual EPS Info Date
Earnings Report -0.090 USD Q1 2025 Earnings Release 05/01/2025
Earnings Report -0.080 USD Q4 2024 Earnings Release 02/24/2025
Earnings Report -0.080 USD Q3 2024 Earnings Release 10/30/2024
Earnings Report -0.090 USD Q2 2024 Earnings Release 08/06/2024
Annual General Meeting -0.990 USD Annual General Meeting 06/14/2024
Earnings Report -0.060 USD Q1 2024 Earnings Release 05/01/2024
Earnings Report -0.050 USD Q4 2023 Earnings Release 02/20/2024
Earnings Report -0.030 USD Q3 2023 Earnings Release 11/07/2023
Earnings Report -0.020 USD Q2 2023 Earnings Release 08/09/2023
Annual General Meeting -0.410 USD Annual General Meeting 05/23/2023
Earnings Report -1.430 USD Q1 2023 Earnings Release 05/11/2023
Earnings Report -0.070 USD Q4 2022 Earnings Release 03/09/2023
Earnings Report -0.140 USD Q3 2022 Earnings Release 11/09/2022
Earnings Report -0.170 USD Q2 2022 Earnings Release 08/11/2022
Annual General Meeting -0.960 USD Annual General Meeting 06/16/2022
Earnings Report -0.220 USD Q1 2022 Earnings Release 05/11/2022
Earnings Report -0.280 USD Q4 2021 Earnings Release 03/17/2022

Summit Therapeutics Profile

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
8
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.
OSZAR »